Baricitinib in hospitalised patients with COVID-19: A meta-analysis of randomised controlled trials

BACKGROUND: To date, only dexamethasone and tocilizumab have been shown to reduce mortality in patients with COVID-19. Baricitinib is a Janus kinase 1/2 inhibitor with known anti-inflammatory and anti-viral properties. We performed a meta-analysis of RCTs assessing the role of baricitinib in hospita...

Descripción completa

Detalles Bibliográficos
Autores principales: Selvaraj, Vijairam, Finn, Arkadiy, Lal, Amos, Khan, Mohammad Saud, Dapaah-Afriyie, Kwame, Carino, Gerardo P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163705/
https://www.ncbi.nlm.nih.gov/pubmed/35677732
http://dx.doi.org/10.1016/j.eclinm.2022.101489

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163705/
https://www.ncbi.nlm.nih.gov/pubmed/35677732
http://dx.doi.org/10.1016/j.eclinm.2022.101489

Ejemplares similares